Drug intelligence / Profile preview

FWB1313

Development stage: Preclinical
Lead developer: Forward Pharma

Overview

FWB1313 is a biologic therapeutic candidate developed by Forward Pharmaceuticals Co., Ltd. It is designed to target Interleukin-13 (IL-13), a key cytokine involved in Type 2 inflammation. IL-13 plays a central role in the pathophysiology of various allergic and inflammatory diseases, including asthma, atopic dermatitis, and idiopathic pulmonary fibrosis. By neutralizing IL-13, FWB1313 aims to modulate the inflammatory response. As of 2024, the asset is in the IND-enabling stage of development.

Targets

IL-13 (Interleukin-13)

Beyond the preview

Go deeper on FWB1313.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FWB1313.

Explore the full profile